Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

David Bernard

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1557-2074; OpenAlex author ID A5047858570. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 2

  1. Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Last author DOI 10.1186/s43556-023-00116-4↗
  2. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Last author DOI 10.18632/oncotarget.8527↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Delphine Goehrig · 1 shared paper, 2023 · strength 0.18
  2. Sara Jaber · 1 shared paper, 2023 · strength 0.18
  3. Raphaël Maréchal · 1 shared paper, 2016 · strength 0.05
  4. Magali Svrcek · 1 shared paper, 2016 · strength 0.05
  5. Jerome F. Cros · 1 shared paper, 2016 · strength 0.05
  6. Laurent Bartholin · 1 shared paper, 2016 · strength 0.05
  7. Johann Gout · 1 shared paper, 2016 · strength 0.05
  8. Christelle de la Fouchardière · 1 shared paper, 2016 · strength 0.05
  9. Benjamin Le Calvé · 1 shared paper, 2016 · strength 0.05
  10. Jean‐Baptiste Bachet · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.